Delhi, India, April 09, 2015 --(PR.com
)-- DelveInsight, a Business Consultant Firm, has released its new analytical reports which are highlighting key areas of the Pharmaceuticals sector. The reports include Anticoagulants and Programmed cell death 1 (PD-1) Inhibitors Analytical Reports. These Reports provides the latest developments on currently marketed and pipeline products and strategic insight on market trends and barriers in global Blood Coagulation and Cancer markets. These Reports enable the client to plan strategies and evaluate new market opportunities.
DelveInsight Report, “Anticoagulants-Competitive Landscape, Market & Pipeline Analysis, Forecasted Market Size 2015-2018” analyzes the worldwide market of Anticoagulants, information of marketed molecules, detail profiling of Pipeline assets. DelveInsight portrayed the Anticoagulants markets as a most potential market and have lot of future scope in market. Mostly anticoagulants are being used in Venous Thromboembolism and Atrial Fibrillation. According to DelveInsight analysis, the global VTE therapeutics market was worth USD 4 billion in 2014 and is expected to reach USD 5.5 billion by 2018 with a Compound Annual Growth Rate (CAGR) of 8.29%.
DelveInsight Report, “Programmed cell death 1 (PD-1) Inhibitors” analyzes the market of PD-1 and PD-L1 inhibitors, their pathways, MOAs, marketed molecules, detail profiling of Pipeline assets highlighting all the indications. DelveInsight Analysis predicts that PD-1 and PD-L1 inhibitors are among the upcoming and highly growing fields in biopharmaceutical industry. Most of these immunotherapeutic are being used in Oncology. Future competitive landscape of PD-1 and PD-L1 inhibitors is estimated to be very strong. There are 2 marketed products of PD-1 and PD-L1 inhibitors. According to DelveInsight analysis, Merck's Keytruda and Bristol’s Opdivo believe to be major blockbusters in the market.
For further information and Sample Pages, mail at info@delveInsight.com